摘要
目的探讨MG7抗体靶向紫杉醇纳米药物治疗人胃癌裸鼠移植瘤的疗效。方法采用裸鼠BGC-823胃腺癌动物模型,每组6只,随机分配至设立的生理盐水对照组、载体材料组、紫杉醇常规药物组、非靶向紫杉醇纳米药物组、MG7抗体靶向紫杉醇纳米药物组。采用尾静脉给药方式,动态观察并测定肿瘤的体积、瘤质量抑瘤率,评价治疗效果,并观察实验期间动物的全身情况及相对体质量变化,评价毒副作用。结果 MG7抗体靶向紫杉醇纳米药物组人胃癌移植瘤表现出明显的体积抑制和瘤质量抑制,抑瘤率分别为84.6%和84.5%,显著高于紫杉醇常规药物组(45.1%,48.7%)和非靶向紫杉醇纳米药物组38.7%,42.2%),而且MG7抗体靶向紫杉醇纳米药物组的小鼠体质量与其它各组比较相对平稳,且饮食活动正常,对正常组织的毒副作用明显减轻。结论 MG7抗体靶向紫杉醇纳米药物具有良好的高效低毒体内抗肿瘤作用,作为一种新型药物载体显示了良好的应用前景。
Objective To study the curative effect of MG7 antibody targeting paclitaxel nano - drugs on human gastric cancer xenografts in nude mice. Methods Human gastric cell line BGC - 823 was implanted into 30 nude mice Diugs were injected through the caudal vein in 5 different groups with established experimental models Tumor growth was monitored once other day. Results The growth speed of tumro in the group of MG7 antibody targeting paelitaxel nano - drugs was signifieantly slower than the other groups The rates of tumor restrain in tumor weight and tumor volume of the MG7 antibody targeting paclitaxel nano - drugs group were 84.6% and 84.5% respectively, remarkably higher than other groups. The side - effect and toxicity in the MG7 antibody targeting paclitaxel nano - drugs group were significantly less than in the other groups. Conclusion MG7 antibody targeting paclitaxel nano - drugs can inhibit the growthof tumor,which indicates a favorable fore- ground for its clinical application.
出处
《中国医学创新》
CAS
2011年第17期3-5,共3页
Medical Innovation of China
